BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
Macquarie maintains outperform on Jubilant Life Sciences
Jubilant Life shares are likely to re-rate from current valuation, says Macquarie. We expect free cash flow generation to be stable. We see scale-up of speciality business as a trigger for the stock. The company will continue to show consistent performance. Financial discipline with expanding pharma contribution is positive.